Allergic rhinitis management: what’s next?

References

• Price D, Smith P, Hellings P, et al. Current controversies and challenges in allergic rhinitis management. Expert Rev Clin Immunol. 2015;11(11):1205–1217.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Bewick M, Arnavielhe S, et al. Work productivity in rhinitis using cell phones: the MASK pilot study. Allergy. 2017;72(10):1475–1484.
   PubMed Web of Science ®Google Scholar
• Casale TB, Onder RF, Berkowitz RB, et al. Nasal carbon dioxide used as needed in the symptomatic treatment of seasonal allergic rhinitis. J Allergy Clin Immunology: In Pract. 2017;6(1):183–189.
   Google Scholar
• Roberts G, Pfaar O, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis. Allergy. 2017. [Epub ahead of print]
   Google Scholar
• Bernstein JA, Davis BP, Picard JK, et al. A randomized, double-blind, parallel trial comparing capsaicin nasal spray with placebo in subjects with a significant component of nonallergic rhinitis. Ann Allergy Asthma Immunol. 2011;107(2):171–178.
   PubMed Web of Science ®Google Scholar
• Stokes JR, Romero FA Jr., Allan RJ, et al. The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms. J Allergy Clin Immunol. 2012;129(2):409–12, 12.e1–2.
   PubMed Web of Science ®Google Scholar
• Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131(5):1288–96.e3.
   PubMed Web of Science ®Google Scholar
• Dantzer JA, Wood RA. The use of omalizumab in allergen immunotherapy. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2018. [Epub ahead of print]
   Google Scholar
• Berings M, Karaaslan C, Altunbulakli C, et al. Advances and highlights in allergen immunotherapy: on the way to sustained clinical and immunologic tolerance. J Allergy Clin Immunol. 2017;140(5):1250–1267.
   PubMed Web of Science ®Google Scholar
• Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006;6(10):761–771.
   PubMed Web of Science ®Google Scholar
• Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129(3):717–25.e5.
   PubMed Web of Science ®Google Scholar
• Nolte H, Bernstein DI, Nelson HS, et al. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2016;138(6):1631–1638.
   PubMed Web of Science ®Google Scholar
• Okubo K, Masuyama K, Imai T, et al. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis. J Allergy Clin Immunol. 2017;139(6):1840–8.e10.
   PubMed Web of Science ®Google Scholar
• Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol. 2010;126(5):969–975.
   PubMed Web of Science ®Google Scholar
• Maloney J, Bernstein DI, Nelson H, et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol. 2014;112(2):146–53.e2.
   PubMed Web of Science ®Google Scholar
• Nelson HS, Makatsori M, Calderon MA. Subcutaneous immunotherapy and sublingual immunotherapy: comparative efficacy, current and potential indications, and warnings – United States versus Europe. Immunol Allergy Clin North Am. 2016;36(1):13–24.
   PubMed Web of Science ®Google Scholar
• Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? J Allergy Clin Immunol. 2016;137(2):339–49.e10.
   PubMed Web of Science ®Google Scholar
• Guez S, Vatrinet C, Fadel R, et al. House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy. 2000;55(4):369–375.
   PubMed Web of Science ®Google Scholar
• Hirsch T, Sahn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol. 1997;8(1):21–27.
   PubMed Web of Science ®Google Scholar
• Senti G, Von Moos S, Tay F, et al. Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials. Allergy. 2015;70(6):707–710.
   PubMed Web of Science ®Google Scholar
• Senti G, Graf N, Haug S, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol. 2009;124(5):997–1002.
   PubMed Web of Science ®Google Scholar
• Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A. 2008;105(46):17908–17912.
   PubMed Web of Science ®Google Scholar
• Senti G, Crameri R, Kuster D, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012;129(5):1290–1296.
   PubMed Web of Science ®Google Scholar
• Witten M, Malling HJ, Blom L, et al. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J Allergy Clin Immunol. 2013;132(5):1248–52.e5.
   PubMed Web of Science ®Google Scholar
• Makatsori M, Pfaar O, Lleonart R, et al. Recombinant allergen immunotherapy: clinical evidence of efficacy – a review. Curr Allergy Asthma Rep. 2013;13(4):371–380.
   PubMed Web of Science ®Google Scholar
• Incorvaia C, Montagni M, Ridolo E. The efficiency of peptide immunotherapy for respiratory allergy. Expert Rev Clin Pharmacol. 2016;9(6):831–837.
   PubMed Web of Science ®Google Scholar
• Larché M. Peptide immunotherapy for allergic diseases. Allergy. 2007;62(3):325–331.
   PubMed Web of Science ®Google Scholar
• Couroux P, Patel D, Armstrong K, et al. Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2015;45(5):974–981.
   PubMed Web of Science ®Google Scholar
• Ellis AK, Frankish CW, O’Hehir RE, et al. Treatment with grass allergen peptides improves symptoms of grass pollen-induced allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2017;140(2):486–496.
   PubMed Web of Science ®Google Scholar
• Focke-Tejkl M, Valenta R. Safety of engineered allergen-specific immunotherapy vaccines. Curr Opin Allergy Clin Immunol. 2012;12(5):555–563.
   PubMed Web of Science ®Google Scholar
• Ricketti PA, Alandijani S, Lin CH, et al. Investigational new drugs for allergic rhinitis. Expert Opin Investig Drugs. 2017;26(3):279–292.
   PubMed Web of Science ®Google Scholar
• Tulic MK, Fiset PO, Manoukian JJ, et al. Role of toll-like receptor 4 in protection by bacterial lipopolysaccharide in the nasal mucosa of atopic children but not adults. Lancet. 2004;363(9422):1689–1697.
   PubMed Web of Science ®Google Scholar
• Drachenberg KJ, Wheeler AW, Stuebner P, et al. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy. 2001;56(6):498–505.
   PubMed Web of Science ®Google Scholar
• DuBuske LM, Frew AJ, Horak F, et al. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc. 2011;32(3):239–247.
   PubMed Web of Science ®Google Scholar
• Gawchik SM, Saccar CL. Pollinex Quattro Tree: allergy vaccine. Expert Opin Biol Ther. 2009;9(3):377–382.
   PubMed Web of Science ®Google Scholar
• Casale TB, Cole J, Beck E, et al. CYT003, a TLR9 agonist, in persistent allergic asthma – a randomized placebo-controlled Phase 2b study. Allergy. 2015;70(9):1160–1168.
   PubMed Web of Science ®Google Scholar
• Horak F. VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis. Expert Opin Investig Drugs. 2011;20(7):981–986.
   PubMed Web of Science ®Google Scholar